en · de · es · pt
tirzepatide-notes.peptides1126.com › Faq › Dual Incretin Receptor Agonism — What the Evidence Shows

Dual Incretin Receptor Agonism — What the Evidence Shows

By Editorial Desk · published 2025-11-20 · last reviewed 2026-01-12 · Faq

稳定性 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-01-12. Numbers and descriptions here follow the published literature rather than marketing material.

Dual Incretin Receptor Agonism

Tirzepatide is a synthetic peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The molecule contains 39 amino acids and features a C20 fatty diacid moiety attached via a linker, which promotes albumin binding and extends its circulating half-life. Its sequence incorporates non-natural amino acids and modifications that reduce susceptibility to degradation by dipeptidyl peptidase-4. This dual receptor activity distinguishes it from selective GLP-1 receptor agonists.

The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.

In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.

储存处理与检测方法

质量控制环节关注外观、含量、纯度、有关物质、水分与微生物限度等项目。检测结果需要有对照品和系统适用性数据支持,单次测定不足以判定批次的稳定性。实验室之间方法转移时,色谱柱品牌与梯度差异常导致保留时间漂移,因此方法验证十分必要。

固体状态的 tirzepatide 通常以冻干粉形式保存,推荐在低温、避光、干燥条件下存放,常见区间为 2 至 8 摄氏度,长期保存可考虑更低温度并避免反复冻融。冻融循环会导致肽链聚集或析出,从而影响后续定量结果。容器密封性与湿度控制同样是稳定性研究中反复强调的因素。

溶解操作一般使用注射用水或适宜的水性缓冲液,必要时加入少量助溶剂以改善溶解速度,但应避免剧烈涡旋振荡,因为剪切力可能促进聚集。配制后的溶液在冷藏条件下的稳定时间通常短于固体形态,具体时限取决于浓度、缓冲体系与容器材质。是否加入防腐成分,则取决于用途是否为多次取样。

Tirzepatide at a glance

PropertyValueNotes
Molecular classSynthetic peptideDual GIP/GLP-1 receptor agonist
Amino acid count39Contains non-natural residues
ModificationC20 fatty diacidAttached via linker; promotes albumin binding
Half-lifeApproximately 5 daysSupports once-weekly dosing
Primary routeSubcutaneous injectionNot for intravenous use

Tirzepatide Pharmacology and Development History

The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.

Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.

Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.

Related pages on this site

Background And Receptor Pharmacology

Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.

Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.

Further detail

== Biosynthesis == Oxaloacetate forms in several ways in nature. A principal route is upon oxidation of L-malate, catalyzed by malate dehydrogenase, in the citric acid cycle. Malate is also oxidized by succinate dehydrogenase in a slow reaction with the initial product being enol-oxaloacetate. It also arises from the condensation of pyruvate with carbonic acid, driven by the hydrolysis of ATP:

The factors responsible for differences in psychoactive and hallucinogenic effects between different psychedelics are incompletely understood but may include (1) differences in selectivity for the serotonin 5-HT2A receptor or off-target activity; (2) differences in functional selectivity for different serotonin 5-HT2A receptor downstream signaling pathways; and (3) differences in patterns or balances of distribution to different brain areas. Various approaches are available for estimating equivalent doses of psychedelics between animals and humans. Examples include allometric scaling formulas and receptor occupancy studies.

=== Advertisements === Being the product of a Chicago company, Ferrara Pan was a prominent sponsor of The Bozo Show on WGN-TV (along with its national superstation feed), with Lemonhead specifically promoted, and a gift package of various Ferrara Pan candies often being given as a close-bucket prize during the "Grand Prize Game". In the 1980s, Lemonhead candy advertisements were mostly centered around sports. The commercials followed a similar pattern and featured a children's sports team; the player who made a mistake would be labeled the "lemonhead". In the 2010s, Lemonhead candy commercials featured athletes as well as the Lemonhead mascot. The mascot was pictured alongside popular athletes scoring in games or otherwise achieving athletic success. In 2014, the company rebranded the mascot to feature a more mature figure as the face of Lemonhead candies.

The set of data generated by the subset of subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment, according to the underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of major protocol violations. (ICH E9) Pharmacokinetics

Sources: en.wikipedia.org

Supporting material

== Awards == 2015 Sundance Film Festival Winner, Special Jury Award for Dramatic Feature: Advantageous Nominee, Grand Jury Prize for Dramatic Feature: Advantageous LA Asian Pacific Film Fest Winner, Editing, score, and directing awards for Advantageous (feature) - 2015 Winner, Golden Reel Award for Excellence in Short Film: Advantageous - 2013 2012 Rhode Island Horror Film Festival Winner, Best Science Fiction Film: Advantageous (Short) Asian American International Film Festival Winner, Best Narrative: Half Life - 2008 Winner, Emerging Director Award for Best Feature: Half Life - 2008 Nominee, Excellence in Short Filmmaking Award: Futurestate - 2013 Austin Fantastic Fest Nominee, Short Film Award: Advantageous (short) - 2012 Cleveland International Film Festival Nominee, Best Women's Short Film: Advantageous (short) - 2013 Nominee, Best Live Action Short Film: Advantageous (short) - 2013 Film Independent Spirit Awards Nominee, John Cassavetes Award: (2016) Shared with Jacqueline Kim, Robert M.

=== Pregnancy and breastfeeding === Ixazomib and lenalidomide are teratogenic in animal studies. The latter is contraindicated in pregnant women, making this therapy regimen unsuitable for this group. It is not known whether ixazomib or its metabolites pass into the breast milk.

They built on the character of the Aperture Science facility, providing a deeper story for GLaDOS and Aperture's CEO Cave Johnson, as well as developing several concepts for "personality cores" that ultimately led to the creation of Wheatley. Portal 2 received similar acclaim to its predecessor at launch, garnering a Metacritic score of 95 out of 100. Valve has continued to support the game through the release of two separate downloadable content packages, one introducing a new co-operative campaign, and a second that incorporated an easy-to-learn level editor that allowed players to make their own test chambers and share these through the Steam Workshop to others. An alternate version of Portal 2 designed for educational use was developed for Valve's Steam for Schools program, and was made available for free. While experimenting with VR systems in 2017, Valve attempted to implement Portal-like gameplay, but early playtesters found the game's titular mechanic disorienting in VR. Valve instead returned to the Half-Life series and released Half-Life: Alyx in 2020. In April 2022, Erik Wolpaw urged Valve to make Portal 3, saying, "I am... not getting any younger. We are reaching the point where – it's crazy to think – [we're] literally going to be too old to work on Portal 3. So we should just do it." In September, Ellen McLain also called for Portal 3, stating that she was willing to star in it, and asked fans to "write in. Email Valve. You've got my blessing".

Iodine-131 is used for unsealed source radiotherapy in nuclear medicine to treat several conditions. It can also be detected by gamma cameras for diagnostic imaging, however it is rarely administered for diagnostic purposes only; imaging will normally be done following a therapeutic dose. Use of the 131I as iodide salt exploits the mechanism of absorption of iodine by the normal cells of the thyroid gland.

But a problem arose for the NRL researchers because naval materials, e.g., ship-plate steel, are not perfectly elastic but undergo significant plastic deformation at the tip of a crack. One basic assumption in Irwin's linear elastic fracture mechanics is small scale yielding, the condition that the size of the plastic zone is small compared to the crack length. However, this assumption is quite restrictive for certain types of failure in structural steels though such steels can be prone to brittle fracture, which has led to a number of catastrophic failures. Linear-elastic fracture mechanics is of limited practical use for structural steels and Fracture toughness testing can be expensive.

Sources: en.wikipedia.org

Supporting material

==== Opioids ==== The use of opioids is controversial. As of 2015, no opioid is approved for use in this condition by the FDA. A 2016 Cochrane review concluded that there is no good evidence to support or refute the suggestion that oxycodone, alone or in combination with naloxone, reduces pain in fibromyalgia. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) in 2014 stated that there was a lack of evidence for opioids for most people. The Association of the Scientific Medical Societies in Germany in 2012 made no recommendation either for or against the use of weak opioids because of the limited amount of scientific research addressing their use in the treatment of fibromyalgia. They strongly advise against using strong opioids. The Canadian Pain Society in 2012 said that opioids, starting with a weak opioid like tramadol, can be tried but only for people with moderate to severe pain that is not well-controlled by non-opioid painkillers. They discourage the use of strong opioids and only recommend using them while they continue to provide improved pain and functioning. Healthcare providers should monitor people on opioids for ongoing effectiveness, side effects, and possible unwanted drug behaviors. A 2015 review found fair evidence to support tramadol use if other medications do not work. A 2018 review found little evidence to support the combination of paracetamol (acetaminophen) and tramadol over a single medication.

for molecular models that are more realistic than rigid elastic spheres, such as those incorporating intermolecular attractions. Doing so is necessary to reproduce the correct temperature dependence of

Chanler, son of John Winthrop Chanler '47, husband of Amélie Rives Troubetzkoy Albert Payson Terhune (1893), author, dog breeder, journalist, Further Adventures of Lad Guy Wetmore Carryl (1895), humorist, Fables for the Frivolous Melville Henry Cane (1900), poet; winner of the Robert Frost Medal in 1971 Joyce Kilmer (1908), poet and author of Trees Randolph Bourne (1912), essayist and public intellectual Harold Lamb (1915), writer, screenwriter Gustav Davidson (1919), poet, secretary of the Poetry Society of America Paul Gallico* (1919), author of The Poseidon Adventure Louis Zukofsky (1922), co-founder and leading theorist of the Objectivist poets James Warner Bellah (1923), Western and pulp writer whose stories formed the basis of such John Ford classics as Fort Apache, She Wore a Yellow Ribbon, and Rio Grande. Corey Ford* (1923), humorist, The John Riddell Murder Case Henry Morton Robinson (1923), author of The Cardinal and A Skeleton Key to Finnegans Wake Cornell Woolrich (1923), mystery writer and author of Rear Window Clifford Dowdey (1925), author on the American Civil War Herman Wouk (1934), author of War and Remembrance and winner of the Pulitzer Prize for Fiction for The Caine Mutiny John Berryman (1936), winner of the Pulitzer Prize for Poetry Robert Paul Smith (1936), author of Where Did You Go? Out. What Did You Do? Nothing.

Residency or postgraduate training is a stage of graduate medical education. It refers to a qualified physician (one who holds the degree of MD, DO, MBBS/MBChB), veterinarian (DVM/VMD, BVSc/BVMS), dentist (DDS or DMD), podiatrist (DPM), optometrist (OD), pharmacist (PharmD), physical therapist (DPT), or Medical Laboratory Scientist (Doctor of Medical Laboratory Science) who practices medicine or surgery, veterinary medicine, dentistry, optometry, podiatry, clinical pharmacy, physical therapy, or Clinical Laboratory Science, respectively, usually in a hospital or clinic, under the direct or indirect supervision of a senior medical clinician registered in that specialty such as an attending physician or consultant. The term residency is named as such due to resident physicians (resident doctors) of the 19th century residing at the dormitories of the hospital in which they received training. In many jurisdictions, successful completion of such training is a requirement in order to obtain an unrestricted license to practice medicine, and in particular a license to practice a chosen specialty. In the meantime, they practice "on" the license of their supervising physician. An individual engaged in such training may be referred to as a resident physician, house officer, registrar or trainee depending on the jurisdiction. Residency training may be followed by fellowship or sub-specialty training.

Duramycin has completed phase II clinical trials for the treatment of cystic fibrosis. Other bioactive RiPPs include the antibiotics cyclothiazomycin and bottromycin, the ultra-narrow spectrum antibiotic plantazolicin, and the cytotoxin patellamide A. Streptolysin S, the toxic virulence factor of Streptococcus pyogenes, is also a RiPP. Thyroxine is an example of a mammalian RiPP due to its biosynthetic origin as thyroglobulin.

Sources: en.wikipedia.org

Frequently asked questions

What receptors does tirzepatide target?

It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.

How is tirzepatide administered?

It is given as a subcutaneous injection. Its long half-life supports weekly dosing.

Is tirzepatide a natural peptide?

No, it is synthetic. It contains non-natural amino acids and a fatty acid modification.

固体粉末应如何存放?

建议在低温、避光、干燥环境中密封保存,常见条件为 2 至 8 摄氏度,长期存放可置于更低温度。应避免反复冻融,并尽量减少容器开启次数。

Network